Genetic Technologies Ltd. (GENE)

1.26
0.02 1.60
NASDAQ : Health Technology
Prev Close 1.28
Open 1.28
Day Low/High 1.24 / 1.31
52 Wk Low/High 0.70 / 2.05
Volume 44.85K
Avg Volume 126.40K
Exchange NASDAQ
Shares Outstanding 16.24M
Market Cap 22.43M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Change Of Chief Executive Officer

Change Of Chief Executive Officer

Appointment Of Chairman

Appointment Of Chairman

Resignation Of Directors

Resignation Of Directors

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share are within range of breaking out and trading higher from current levels.

PHENOGEN SCIENCES SUPPORTS RESEARCH FINDING CLINICAL VALIDATION IS NEEDED FOR GENE PANEL SEQUENCING ASSOCIATED WITH HEREDITARY BREAST CANCER RISK

PHENOGEN SCIENCES SUPPORTS RESEARCH FINDING CLINICAL VALIDATION IS NEEDED FOR GENE PANEL SEQUENCING ASSOCIATED WITH HEREDITARY BREAST CANCER RISK

Clinically validated BREVAGenplus(R) more accurately identifies sporadic breast cancer risk

ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK

ROCKVILLE GYNECOLOGY NOW OFFERING BREVAGenplus(R), A STATE-OF-THE-ART TEST FOR ASSESSING BREAST CANCER RISK

Personalized, Genetically-Based Test Enables Physicians to Tailor Breast Cancer Screening and Reduction Services Based on Individual Risk

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks look poised to break out and trade higher from current levels.

Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test

Genetic Technologies (GENE) Rises Today as More Centers Adopt Breast Cancer Test

Shares of Genetic Technologies Ltd. (GENE) rose Monday after the molecular diagnostics company announced that two new breast health centers will start to offer BREVAGenplus®.

Stalking an Entry in RetailMeNot

Can we wait for it to tell us whether to buy or avoid it.?

PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT

PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT

Findings presented at the 2014 San Antonio Breast Cancer Symposium

Why Genetic Technologies (GENE) Stock Is Spiking Today

Why Genetic Technologies (GENE) Stock Is Spiking Today

Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.